U.S. Ambassador to Nigeria Terence McCulley spoke on Monday in Abuja at the inauguration of a Defense Reference Laboratory, Leadership reports, noting he said the laboratory, “which is the first of its kind in the sub-region,” was supported by U.S. funding. According to the newspaper, McCulley said the Reference Laboratory Program is part of U.S. assistance to Nigeria through a partnership between the U.S. Department of Defense (DOD) and Nigeria’s Ministry of Defense (NMOD) through the Walter Reed Program (WRP-N) and the Emergency Plan Implementation Committee (EPIC), which began in 2005 (8/30).
The Center for Global Health Policy’s “Science Speaks” blog examines a recent study that found only slightly more than 44 percent of women in the Nyanza province of Kenya deliver their infants in a health care facility, with many women citing fear of stigma and discrimination as a reason for not attending clinics for prenatal care. Janet Turan of the University of Alabama led the study, published in the August edition of PLoS Medicine, as well as a literature review showing the impact of stigma and discrimination on efforts to prevent mother-to-child HIV transmission, according to the blog. The researchers “conclude that efforts to address HIV-related stigma in and out of health settings are needed, if efforts targeting maternal mortality and parent to child HIV transmission are to succeed,” the blog writes (Barton, 8/29).
Brazil is expanding its national HIV/AIDS treatment program to include about 35,000 additional people, the Associated Press/Seattle Times reports. “Ronaldo Hallal of the [health] ministry’s Sexually Transmitted Disease Department said people with 500 or fewer CD4 cells per cubic millimeter will receive antiretroviral HIV treatment,” increasing the cutoff from 350 or less CD4 cells per cubic millimeter prior to the expansion, the news service writes. The Ministry of Health noted on its website that the expansion will require spending an additional 120 million reals, or $60,000, annually, according to the news service, which adds, “Hallal said Brazil already spends 1.2 billion reals ($600 million) each year in its free anti-AIDS program that is currently treating 223,000 people.” The AP notes Health Minister Alexandre Padilla said in a statement, “Brazil will be the only large country in the world to offer this kind of treatment that will reduce the risk of opportunistic infections like tuberculosis” (8/29).
In this post in the Center for Global Development’s (CGD) “Global Health Policy” blog, Amanda Glassman, director of global health policy and a research fellow at the center, and Denizhan Duran, a research assistant at the center, examine several recent studies evaluating the use of cash transfers as a strategy against HIV/AIDS. They state that “a new generation of cash transfer programs in sub-Saharan Africa is reducing new infections and HIV-related risky behavior — and documenting the gains — while also providing consumption, nutrition, education, and mental health benefits to the orphans and vulnerable children who are the primary targets of some programs.” Glassman and Duran conclude, “With the new batch of evaluation results on cash transfers, there may be more reasons to invest in these kinds of programs, particularly the at-scale national programs targeted to the poor” (8/8).
“The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria has approved 45 new two-year grants, from 37 countries, totaling $419.2 million, to fund essential prevention, treatment, and care services provided to the people affected by the three diseases,” according to a Global Fund press release. “Another 11 proposals worth a total of $91.2 million were sent back for revision, and are subject to a further independent technical review before they can be approved,” the press release adds, noting the grant approvals are part of the Transitional Funding Mechanism and “will bridge the financing of essential interventions until the next opportunity to apply for grants” (8/28). According to the U.N. News Centre, the Global Fund “has approved funding of $22.9 billion for more than 1,000 programs in 151 countries, and helped programs provide AIDS treatment for 3.6 million people, anti-tuberculosis treatment for 9.3 million people, and 270 million insecticide-treated nets for the prevention of malaria” (8/28).
Gilead Sciences Signs Deals With 3 Indian Pharmaceutical Companies To Promote Low-Cost HIV Drugs In Developing Countries
Gilead Sciences Inc. announced Thursday that it plans to partner with Mylan Inc., Ranbaxy Laboratories Ltd. and Strides Arcolab Ltd. “to promote access to high-quality, low-cost generic versions of Gilead’s HIV medicine emtricitabine in developing countries,” the Wall Street Journal reports (Stevenson, 8/2). Gilead signed deals with the three Indian companies “to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug emtricitabine in developing countries,” Reuters reports, noting that under the deals, Gilead “will provide technology and funding to help reduce manufacturing costs of the drug, the companies said” (Kuber, 8/2).
In this post in the PLoS “Speaking of Medicine” blog, Judit Rius Sanjuan, a lawyer from Barcelona, Spain, and the U.S. manager of the Access Campaign at Medecins Sans Frontieres (MSF), says the Trans-Pacific Partnership (TPP), a regional trade agreement that currently involves 11 countries but could expand to include other countries in the Asia-Pacific region, “threatens to set a dangerous precedent with damaging implications for developing countries where MSF works, and beyond.” “Negotiations are being conducted in secret, but leaked drafts of the agreement outline U.S. aggressive intellectual property (IP) demands that that could severely restrict access to affordable, life-saving medicines for millions of people,” she writes, concluding, “At this pivotal moment in the fight against AIDS, when the scientific, medical and policy tools needed to reverse the epidemic are finally at hand, … the U.S. government’s demands in the TPP will threaten so much of what has been achieved so far, and will make the vision of an AIDS-free generation impossible, or at least much more expensive” (8/7).
“During the recent [XIX International AIDS Conference (AIDS 2012)] in Washington, D.C., exciting breakthroughs in HIV prevention, treatment, and care — even a possible cure — took center stage,” but, “despite recent advances, many men and women remain at risk of HIV as a result of structural issues that fuel and have an impact on the epidemic,” Molly Fitzgerald, technical advisor for AIDSTAR-One, writes in this post in USAID’s “Impact Blog.” “Addressing gender inequality, poverty, stigma, and other social, economic, cultural, and legal factors is necessary to create an ‘enabling environment’ for these promising biomedical and behavioral interventions,” she continues, noting, “There is increasing agreement worldwide that structural issues are too often overlooked where HIV prevalence remains high” (8/16).
In this post in Global Post’s “Global Pulse” blog, Mitchell Warren, executive director of AVAC, and Chris Collins, vice president and director of public policy at amfAR, write that “the world needs a business plan to end AIDS.” They continue, “To us, ending the epidemic means drastically reducing new HIV infections, while preserving the health of everyone living with HIV,” adding, “This is an ambitious vision, and it is achievable if we make smart use of the HIV prevention and treatment options available today, while continuing the search for a vaccine and a cure. It will require clear priorities, ambitious and achievable targets, sustained funding and effective ways to hold ourselves accountable for progress.”
“Former President Bill Clinton delivered an energizing ‘call to action’ at the closing session of [the XIX International AIDS Conference (AIDS 2012)], encapsulating the high hopes and the sobering challenges facing the fight against global HIV/AIDS,” Janet Fleischman, a senior associate at the Center for Strategic & International Studies’ (CSIS) Global Health Policy Center, writes in the center’s “Smart Global Health” blog. “In order to build the necessary political momentum going forward, he focused on certain key areas: supporting greater commitments from affected countries, driving down the costs of treatment, and creating innovative financing mechanisms to accompany traditional donor funding,” she notes, and highlights key messages from his Closing Session address (7/31). A webcast of the session is available online from the Kaiser Family Foundation.